Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pandemic H1N1 vaccine immunogenicity and safety study in children 3 to 9 years old
2009-015960-32Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of Q-Pan H1N1 and FLU-Q-PAN H7N9 Formulation 1 + AS03A in influenza A virus infection (H1N1) (2 arms), sponsored by GSK. Primary endpoints: Humoral immune response meeting CHMP criteria and H1N1 hemagglutination inhibition antibody response after each vaccination. Started Oct 2009; status: completed.
02
Drugs
Q-Pan H1N1FLU-Q-PAN H7N9 Formulation 1 + AS03A
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-015960-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015960-32.